Tesla Stock Jumps After UBS Upgrade, AI5

Tesla stock rose after a UBS upgrade and Elon Musk's AI5 chip tape-out, boosting trading flows and optimism ahead of Q1 2026 earnings on April 22.

April 16, 2026·2 min read
View all news articles
Flat vector of a car chip hybrid representing Tesla stock momentum tied to UBS upgrade and AI5 chip tape-out milestone.

KEY TAKEAWAYS

  • UBS upgraded Tesla to Neutral with a $352 price target on April 15.
  • Elon Musk announced an AI5 chip tape-out and teased an AI6 successor.
  • Moves arrived ahead of Tesla's April 22 Q1 2026 earnings report.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Tesla stock rose on April 15 after UBS upgraded its rating and CEO Elon Musk announced an AI5 chip tape-out, following vehicle software updates and Dutch approval for supervised Full Self-Driving. These developments came ahead of the company’s April 22 Q1 2026 earnings report.

Analyst Ratings and Valuation Trends

UBS upgraded Tesla to Neutral from Sell, setting a $352 price target and citing a balance between near-term demand risks and Tesla’s long-term "physical AI" opportunity. TD Cowen lowered its price target to $490 from $519 but maintained a Buy rating, reflecting differing views on Tesla’s near-term business versus its technology prospects.

The analyst consensus remains mixed, with 19 Buy, 15 Hold, and 9 Sell recommendations, producing an average price target of $398.61. Morningstar raised its fair-value estimate to $400 from $300, attributing the increase to gains in robotaxi and humanoid-robot valuation, accelerating adoption of autonomous software, lower per-vehicle costs, and growth in charging and energy storage. Morningstar’s model assumes about $170 billion in capital spending over the next decade.

Analysts expect first-quarter 2026 earnings per share (EPS) of $0.37, roughly 37% year-over-year growth. By comparison, the prior quarter showed EPS of $0.50, revenue of $24.9 billion (down 3.1% year-over-year), and a net margin of 4.0%.

The mix of rating changes and target adjustments has focused trading attention ahead of the earnings report. UBS’s upgrade contrasts with TD Cowen’s trimmed target and the broader split on the Street, highlighting competing views on near-term demand and the valuation premium tied to autonomy and robotics.

AI Chip Milestone and Regulatory Approval

On April 15, Elon Musk announced the tape-out of the AI5 chip, a manufacturing milestone toward production for Tesla’s in-vehicle and robot applications, and teased a successor, AI6. The company also rolled out vehicle software updates that added in-car AI features, including a voice assistant and Full Self-Driving version 14.3, emphasizing software as a future revenue driver.

Dutch authorities approved supervised Full Self-Driving for Tesla vehicles, granting the company a regulatory foothold in Europe. While this supports assumptions about a continental rollout, it does not translate into immediate revenue.

Market participants noted near-term risks that could temper enthusiasm, including capital commitments like Terafab, margin pressure, delivery trends, insider selling of roughly 53,804 shares valued at about $20.9 million, and intensifying competition in robotics and robotaxi efforts.

Tesla’s April 22 Q1 2026 earnings report will test whether these analyst re-ratings, chip and software milestones, and regulatory steps translate into measurable changes in results or guidance.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 went general; pricing stayed unchanged and Mythos stayed gated, a setup that could shift cloud AI costs and investor positioning.

Abbott Earnings Beat After Exact Sciences Deal

Abbott Earnings Beat After Exact Sciences Deal

Abbott earnings posted revenue and adjusted-profit beats but narrowed FY EPS guidance after the Exact Sciences acquisition, likely pressuring shares.

Hims & Hers Stock Climbs on Peptide Policy Shift

Hims & Hers Stock Climbs on Peptide Policy Shift

Hims & Hers stock rose after praising FDA steps to reassess peptide restrictions, driving trader interest ahead of the July advisory committee review.

J.B. Hunt Q1 Earnings Beat As Margins Expand

J.B. Hunt Q1 Earnings Beat As Margins Expand

J.B. Hunt Q1 earnings showed revenue growth and 70 bps margin expansion April 15, 2026, driven by intermodal volumes and cost cuts that pressured shares.

PepsiCo Earnings Rise on Snacking Rebound

PepsiCo Earnings Rise on Snacking Rebound

PepsiCo earnings beat estimates as price cuts and new snacks lifted U.S. demand, reinforcing annual targets and supporting volume recovery.

IonQ Stock Soars After DARPA Selection

IonQ Stock Soars After DARPA Selection

IonQ stock jumped after a DARPA selection and photonics milestone; management cited a 2026 revenue outlook near $235 million, sparking a multiday rally.